Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without cloretazine® in patients with first relapse of acute myeloid leukemia (AML)

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without cloretazine® in patients with first relapse of acute myeloid leukemia (AML). Blood. 2006; 108(11):557a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.